🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Vancouver
Clinical trial register · Canada

Clinical Trials in Vancouver, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Vancouver 38 Toronto 33 Hamilton 30 Ottawa 24 Kingston 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of British Columbia179 AstraZeneca54 Canadian Cancer Trials Group38 National Cancer Institute (NCI)36 British Columbia Cancer Agency31 Clear sponsor filter
Site location
Vancouver38 Toronto33 Hamilton30 Ottawa24 Kingston22
All 35 locations
Target enrolment
to

Trials with a site in Vancouver

38 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
NCT07341191Mantle Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
Canadian Cancer Trials Group
Phase 2
40
Calgary, Edmonton, Vancouver, Toronto
2026-08-24
Recruiting
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
NCT07390435Cancer
Canadian Cancer Trials Group
Observational
1,000
Calgary, Edmonton, Kelowna, Prince George, Vancouver, Victoria, Saint John, Hamilton
2026-05-15
Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
NCT06880523Hepatocellular Carcinoma
DrugsSTRIDE (durvalumab·Tremelimumab·Lenvatinib·Durvalumab
Canadian Cancer Trials Group
Phase 2
140
Calgary, Kelowna, Vancouver, Hamilton, Kingston, Kitchener, London, Mississauga
2025-10-21
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924Prostate Cancer (Adenocarcinoma)
DrugsApalutamide·Abiraterone·Darolutamide·Enzalutamide
Canadian Cancer Trials Group
Phase 3
830
Edmonton, Vancouver, Winnipeg, Saint John, Greater Sudbury, Hamilton, Kingston, Kitchener
2025-05-28
Recruiting
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
NCT06623461Melanoma
Canadian Cancer Trials Group
Phase 2
128
Abbotsford British Columbia, Surrey, Vancouver, Hamilton, London, Newmarket, Ottawa, Toronto
2025-04-07
Recruiting
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
NCT06641791Advanced Head and Neck Cancer
Canadian Cancer Trials Group
Phase 3
196
Calgary, Edmonton, Vancouver, Winnipeg, Ottawa, Toronto, Montreal, Québec
2025-04-07
Recruiting
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
NCT06391242Cancer Metastatic
Canadian Cancer Trials Group
Phase 3
230
Calgary, Vancouver, Hamilton, Kingston, London, Newmarket, Toronto, Montreal
2025-03-07
Recruiting
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06439225Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
DrugsDocetaxel·Carboplatin
Canadian Cancer Trials Group
Phase 3
236
Calgary, Edmonton, Vancouver, Brampton, Kitchener, London, Ottawa, Toronto
2024-12-30
Recruiting
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
NCT06358469Vulvar Squamous Cell Carcinoma
Canadian Cancer Trials Group
Not applicable
249
Kelowna, Vancouver, Victoria, Hamilton, Toronto, Montreal, Québec, Sherbrooke
2024-12-10
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485Rectal Cancer
DrugsLeucovorin·Capecitabine·Oxaliplatin
Canadian Cancer Trials Group
Phase 3
250
Vancouver, Winnipeg, St. John's, London, Ottawa, Montreal, Regina, Saskatoon
2024-06-26
Recruiting
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
NCT06043427Gastroesophageal Adenocarcinoma
DrugsZanidatamab·Ramucirumab·Paclitaxel
Canadian Cancer Trials Group
Phase 2
168
Calgary, Vancouver, Winnipeg, Halifax, Barrie, Hamilton, Kingston, Kitchener
2024-04-16
Recruiting
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
NCT06182774Multiple Myeloma
DrugsIsatuximab·Daratumumab·Lenalidomide·Dexamethasone
Canadian Cancer Trials Group
Phase 3
570
Edmonton, Kelowna, Vancouver, Winnipeg, Moncton, Saint John, St. John's, Barrie
2024-04-10
Recruiting
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
NCT05998642Non-hodgkin Lymphoma
DrugsIbrutinib·Methotrexate·Rituximab
Canadian Cancer Trials Group
Phase 2
30
Calgary, Vancouver, Hamilton, Ottawa, Toronto, Montreal, Québec, Regina
2024-02-13
Recruiting
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
NCT05601440Breast Cancer
DrugsCFI-402257·Camonsertib·Lunresertib·CFI-400945
Canadian Cancer Trials Group
Phase 2
484
Calgary, Kelowna, Vancouver, Halifax, Hamilton, Kingston, Ottawa, Toronto
2023-06-13
Recruiting
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004Oropharyngeal Cancer
Canadian Cancer Trials Group
Phase 3
510
Vancouver, Winnipeg, Greater Sudbury, Hamilton, Toronto, Montreal, Sherbrooke
2023-02-10
Recruiting
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
NCT05371808Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Canadian Cancer Trials Group
Observational
247
Vancouver, Winnipeg, Saint John, Oshawa, Ottawa, Montreal
2023-01-27
Recruiting
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999Endometrial Cancer
Canadian Cancer Trials Group
Phase 2
393
Calgary, Edmonton, Kelowna, Prince George, Vancouver, Victoria, Barrie, Hamilton
2022-12-19
Recruiting
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
NCT05180097Hodgkin Lymphoma
DrugsBrentuximab Vedotin·Dexamethasone·Gemcitabine·Cisplatin
Canadian Cancer Trials Group
Phase 2
84
Calgary, Vancouver, St. John's, Halifax, Hamilton, London, Ottawa, Toronto
2022-11-01
Recruiting
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT04918186Ovarian Cancer
DrugsENB003·Toripalimab·Durvalumab
Canadian Cancer Trials Group
Phase 2
60
Kelowna, Vancouver, Toronto, Montreal
2022-05-03
Active, closed
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
NCT04663997Prostate Cancer
DrugsLu-PSMA·Docetaxel
Canadian Cancer Trials Group
Phase 2
200
Calgary, Edmonton, Vancouver, London, Toronto, Montreal, Québec, Sherbrooke
2021-08-11
Active, closed
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
NCT04650581Breast Cancer
DrugsIpatasertib·Fulvestrant
Canadian Cancer Trials Group
Phase 3
250
Kelowna, Surrey, Vancouver, Saint John, Halifax, Barrie, Brampton, Hamilton
2021-01-27
Active, closed
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248Lymphoma, B-Cell
DrugsTafasitamab·Glofitamab·Venetoclax·Rituximab
Canadian Cancer Trials Group
Phase EARLY_PHASE1
40
Vancouver, Kingston, Toronto, Montreal
2020-09-02
Active, closed
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04093167Lung Cancer
DrugPembrolizumab
Canadian Cancer Trials Group
Phase 2/3
53
Edmonton, Vancouver, Greater Sudbury, Hamilton, Kingston, Ottawa, Sault Ste. Marie, Toronto
2020-05-26
Recruiting
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
NCT03847649Cancer
DrugsTremelimumab·Prednisone·Durvalumab
Canadian Cancer Trials Group
Phase 2
60
Edmonton, Kelowna, Vancouver, Saint John, Hamilton, Kitchener, Ottawa, Toronto
2020-03-09
Active, closed
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570Bladder Cancer
DrugDurvalumab
Canadian Cancer Trials Group
Phase 2
82
Calgary, Edmonton, Vancouver, Greater Sudbury, Hamilton, Kingston, London, Newmarket
2019-10-25
Active, closed
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
NCT03822897Oropharyngeal Cancer
DrugCisplatin
Canadian Cancer Trials Group
Phase 2
103
Prince George, Vancouver, Winnipeg, St. John's, Hamilton, Kingston, Ottawa, Toronto
2019-06-28
Active, closed
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
NCT03568422Breast Cancer
DrugsCFI-402257·Paclitaxel
Canadian Cancer Trials Group
Phase 1/2
37
Vancouver, Kingston, Ottawa, Toronto
2019-02-05
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391Brain Metastases
DrugMemantine
Canadian Cancer Trials Group
Phase 3
206
Calgary, Edmonton, Vancouver, Halifax, Hamilton, London, Toronto, Greenfield Park
2018-11-22
Active, closed
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693Breast Cancer
Canadian Cancer Trials Group
Phase 3
2,138
Calgary, Edmonton, Abbotsford British Columbia, Kelowna, Prince George, Surrey, Vancouver, Victoria
2018-10-16
Active, closed
Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT03385655Prostate Cancer
DrugsCFI-400945·Adavosertib·Ipatasertib·Savolitinib
Canadian Cancer Trials Group
Phase 2
200
Edmonton, Vancouver, Halifax, Hamilton, London, Ottawa, Toronto, Montreal
2018-08-01
Active, closed
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
NCT03480776Ovarian Cancer Prevention
DrugAcetylsalicylic acid
Canadian Cancer Trials Group
Phase 2
117
Calgary, Vancouver, Winnipeg, St. John's, Kingston, Toronto, Montreal, Québec
2018-07-24
Recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT03297606Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
DrugsTemsirolimus·Bosutinib·Cobimetinib·Vismodegib
Canadian Cancer Trials Group
Phase 2
720
Edmonton, Kelowna, Vancouver, Kingston, London, Ottawa, Toronto, Montreal
2018-03-23
Active, closed
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106Lung Cancer Metastatic
DrugsTremelimumab·Durvalumab
Canadian Cancer Trials Group
Phase 2
301
Edmonton, Surrey, Vancouver, Fredericton, Moncton, Saint John, Cambridge, Greater Sudbury
2017-03-28
Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013Unresectable/Metastatic Melanoma
Canadian Cancer Trials Group
Phase 3
614
Edmonton, Surrey, Vancouver, Victoria, Fredericton, Barrie, Greater Sudbury, Hamilton
2016-10-31
Active, closed
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02436707Lymphoma
DrugsMesna·Ibrutinib·Etoposide·Rituximab
Canadian Cancer Trials Group
Phase 2
129
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Kingston, Ottawa, Toronto
2015-10-27
Active, closed
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
NCT02537418Solid Malignancies
DrugsTremelimumab·Durvalumab
Canadian Cancer Trials Group
Phase 1
153
Calgary, Vancouver, Hamilton, Kingston, Ottawa, Toronto, Montreal
2015-10-16
Active, closed
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
NCT02285816Advanced/Metastatic Solid Tumours
Canadian Cancer Trials Group
Phase 1/2
56
Vancouver, Hamilton, Ottawa, Toronto
2015-01-22
Active, closed
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01396408Advanced Rare Tumours
DrugsTemsirolimus·Sunitinib
Canadian Cancer Trials Group
Phase 2
137
Calgary, Edmonton, Kelowna, Vancouver, Winnipeg, Halifax, Hamilton, London
2012-02-09
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/vancouver

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies with a site in Vancouver that also match the filters currently applied.

How many clinical trials are recruiting in Vancouver?

23 of the 38 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Vancouver), 38 studies
PhaseStudiesRecruitingShare
Phase 2191150%
Phase 311928.9%
Observational225.3%
Phase 1/2205.3%
Not applicable112.6%
Phase 1102.6%
Phase 2/3102.6%
Phase EARLY_PHASE1102.6%

Most active sponsors

Lead sponsors with the most studies (Vancouver)
Lead sponsorStudiesRecruiting
Canadian Cancer Trials Group3823
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.